Bernd Gruhn

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8072672/publications.pdf

Version: 2024-02-01

59 papers 2,583 citations

304368
22
h-index

50 g-index

64 all docs 64
docs citations

64 times ranked 3552 citing authors

#	Article	IF	CITATIONS
1	Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet, The, 2012, 379, 1301-1309.	6.3	324
2	Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet, The, 2014, 383, 436-448.	6.3	322
3	Increasing Mixed Chimerism Is an Important Prognostic Factor for Unfavorable Outcome in Children With Acute Lymphoblastic Leukemia After Allogeneic Stem-Cell Transplantation: Possible Role For Pre-Emptive Immunotherapy?. Journal of Clinical Oncology, 2004, 22, 1696-1705.	0.8	231
4	Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transplantation, 2018, 53, 138-145.	1.3	225
5	Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica, 2017, 102, 865-873.	1.7	206
6	Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplantation, 2004, 33, 189-195.	1.3	174
7	Transplantation of <scp>CD</scp> 3/ <scp>CD</scp> 19 depleted allografts from haploidentical family donors in paediatric leukaemia. British Journal of Haematology, 2014, 165, 688-698.	1.2	109
8	Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. Blood, 2011, 118, 5681-5688.	0.6	92
9	The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis. Blood, 2016, 127, 3281-3290.	0.6	83
10	Monitoring of Epsteinâ€Barr virus load after hematopoietic stem cell transplantation for early intervention in postâ€transplant lymphoproliferative disease. Journal of Medical Virology, 2008, 80, 441-454.	2.5	79
11	Prenatal origin of childhood acute lymphoblastic leukemia, association with birth weight and hyperdiploidy. Leukemia, 2008, 22, 1692-1697.	3.3	67
12	Successful bone marrow transplantation in a patient with DNA ligase IV deficiency and bone marrow failure. Orphanet Journal of Rare Diseases, 2007, 2, 5.	1.2	62
13	Treosulfan-based conditioning regimen for children and adolescents with hemophagocytic lymphohistiocytosis. Haematologica, 2014, 99, 180-184.	1.7	54
14	Pre-emptive therapy with rituximab for prevention of Epstein–Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2003, 31, 1023-1025.	1.3	50
15	Polymorphism of Interleukin-23 Receptor Gene But Not of NOD2/CARD15 Is Associated with Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation in Children. Biology of Blood and Marrow Transplantation, 2009, 15, 1571-1577.	2.0	49
16	Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study. Leukemia, 2009, 23, 1472-1479.	3.3	48
17	Semiquantitative PCR analysis of Epstein-Barr virus DNA in clinical samples of patients with EBV-associated diseases. Journal of Medical Virology, 2001, 65, 348-357.	2.5	43
18	No improvement of survival with reduced-versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. Annals of Oncology, 2011, 22, 1614-1621.	0.6	42

#	Article	IF	CITATIONS
19	Gonadal Function after Busulfan Compared with Treosulfan in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2019, 25, 1786-1791.	2.0	42
20	Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis. Blood Advances, 2020, 4, 1998-2010.	2.5	30
21	Successful treatment of Epstein–Barr virus-induced transverse myelitis with ganciclovir and cytomegalovirus hyperimmune globulin following unrelated bone marrow transplantation. Bone Marrow Transplantation, 1999, 24, 1355-1358.	1.3	29
22	Heparanase polymorphisms: influence on incidence of hepatic sinusoidal obstruction syndrome in children undergoing allogeneic hematopoietic stem cell transplantation. Journal of Cancer Research and Clinical Oncology, 2015, 141, 877-885.	1.2	26
23	Comparison of different rabbit ATG preparation effects on early lymphocyte subset recovery after allogeneic HSCT and its association with EBV-mediated PTLD. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1971-1980.	1.2	25
24	High rates of submicroscopic aberrations in karyotypically normal acute lymphoblastic leukemia. Molecular Cytogenetics, 2015, 8, 45.	0.4	17
25	Prognostic impact of WT1 expression prior to hematopoietic stem cell transplantation in children with malignant hematological diseases. Journal of Cancer Research and Clinical Oncology, 2015, 141, 523-529.	1.2	16
26	Adoptive transfer of exÂvivo expanded regulatory T cells improves immune cell engraftment and therapy-refractory chronic GvHD. Molecular Therapy, 2022, 30, 2298-2314.	3.7	16
27	Multiple viral infections after haploidentical hematopoietic stem cell transplantation in a child with acute lymphoblastic leukemia. Transplant Infectious Disease, 2012, 14, E82-8.	0.7	10
28	Expression Pattern of WT1 Isoforms in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Severe Aplastic Anemia (SAA). Blood, 2011, 118, 2502-2502.	0.6	10
29	Cyclosporin A-induced graft-versus-host disease following autologous bone marrow and stem cell transplantation in hematological malignancies of childhood. Bone Marrow Transplantation, 1998, 21, 901-907.	1.3	9
30	CTLAâ€4 polymorphism rs231775: Influence on relapse and survival after allogeneic hematopoietic stem cell transplantation in childhood. European Journal of Haematology, 2019, 102, 251-255.	1.1	9
31	NOD2/CARD15 gene polymorphisms affect outcome in pediatric allogeneic stem cell transplantation. Blood, 2011, 118, 1181-1184.	0.6	8
32	CTLA-4 polymorphisms: influence on transplant-related mortality and survival in children undergoing allogeneic hematopoietic stem cell transplantation. Journal of Cancer Research and Clinical Oncology, 2018, 144, 587-592.	1.2	8
33	Toll-Like 4 Receptor Variant, Asp299Gly, and Reduced Risk of Hemorrhagic Cystitis after Hematopoietic StemÂCell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 958-963.	2.0	6
34	Detection of relapse after hematopoietic stem cell transplantation in childhood by monitoring of WT1 expression and chimerism. Journal of Cancer Research and Clinical Oncology, 2015, 141, 1283-1290.	1.2	6
35	Superior outcome using cyclosporin A alone versus cyclosporin A plus methotrexate for post-transplant immunosuppression in children with acute leukemia undergoing sibling hematopoietic stem cell transplantation. Journal of Cancer Research and Clinical Oncology, 2015, 141, 1089-1094.	1.2	6
36	Viruses and atypical bacteria in the respiratory tract of immunocompromised and immunocompetent patients with airway infection. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1581-1592.	1.3	6

#	Article	IF	CITATIONS
37	Analysis of risk factors for hepatic sinusoidal obstruction syndrome following allogeneic hematopoietic stem cell transplantation in pediatric patients. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1447-1455.	1.2	6
38	No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease. Bone Marrow Transplantation, 2021, 56, 1550-1557.	1.3	5
39	IL10-592 CC Genotype In the Donor Is Associated with a Significant Decrease of Relapse Rate and a Significant Increase of Event-Free Survival and Overall Survival After Allogeneic Hematopoietic Stem Cell Transplantation In Children with Hematological Malignancies. Blood, 2011, 118, 4459-4459.	0.6	5
40	A pediatric prognostic score for patients undergoing allogeneic hematopoietic stem cell transplantation. European Journal of Haematology, 2014, 93, 509-515.	1.1	4
41	MLLT10 and IL3 rearrangement together with a complex four-way translocation and trisomy 4 in a patient with early T-cell precursor acute lymphoblastic leukemia: A case report. Oncology Reports, 2015, 33, 625-630.	1.2	4
42	No Improvement of Survival for Alveolar Rhabdomyosarcoma Patients After HLA-Matched Versus -Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Compared to Standard-of-Care Therapy. Frontiers in Oncology, 2022, 12, .	1.3	4
43	TLR4 Asp299Gly Variant Confers Strong Protection against BK Virus-Associated Hemorrhagic Cystitis After Hematopoietic Stem Cell Transplantation in Children Blood, 2009, 114, 344-344.	0.6	3
44	Defibrotide (DF) for the Prevention of Hepatic Veno-Occlusive Disease (VOD) in Pediatric Stem Cell Transplantion: Results of a Prospective Phase II/III Randomized, Multicenter Study Blood, 2009, 114, 653-653.	0.6	3
45	Wilms tumor gene single nucleotide polymorphism rs16754 predicts a favorable outcome in children with acute lymphoblastic leukemia. Journal of Cancer Research and Clinical Oncology, 2015, 141, 2221-2228.	1.2	2
46	Continuous molecular remission and regression of side effects after discontinuation of salvage therapy with sorafenib and donor lymphocyte infusions in a young patient with relapsed AML. Annals of Hematology, 2016, 95, 1027-1030.	0.8	2
47	Presence of Preleukemic Clones at Birth in the Majority of Children with B-Lineage Acute Lymphoblastic Leukemia Blood, 2005, 106, 88-88.	0.6	2
48	Interleukin-10-592 polymorphism: impact on relapse and survival after allogeneic hematopoietic stem cell transplantation in children with hematological malignancies. Journal of Cancer Research and Clinical Oncology, 2022, 148, 985-991.	1,2	1
49	Association of recipient and donor interleukin 6 polymorphisms 174 and 597 with outcome after allogeneic hematopoietic stem cell transplantation in children. Journal of Cancer Research and Clinical Oncology, 2022, 148, 255-265.	1.2	1
50	A New Dosing Scheme of ATC-F Prevents Rejection and Maintains Immune Recovery in Haploidentical T and B Cell Depleted Stem Cell Transplantation. Blood, 2012, 120, 4154-4154.	0.6	1
51	Molecular remission using three monoclonal antibodies followed by allogeneic bone marrow transplantation in an infant with refractory ALL. Annals of Hematology, 2020, 99, 1133-1134.	0.8	0
52	Different Epstein-Barr Virus DNA Load and Immune Reconstitution Following Hematopoietic Stem Cell Transplantation Depending on Antithymocyte Globulin Preparation Blood, 2004, 104, 5081-5081.	0.6	0
53	IL23R Arg381Gln Variant in the Donor Confers Strong Protection Against Acute Graft-Versus Host Disease after Hematopoietic Stem Cell Transplantation in Children with Hematological Malignancies Blood, 2007, 110, 2987-2987.	0.6	0
54	Late Relapses of Childhood T-ALL Are Frequently Second T-ALL Blood, 2007, 110, 1435-1435.	0.6	0

#	Article	IF	CITATIONS
55	Clinical Relevance of Minimal Residual Disease and Chimerism for the Detection of Relapse after Hematopoietic Stem Cell Transplantation. Blood, 2008, 112, 338-338.	0.6	0
56	Hemorrhagic Cystitis and BK Virus Infection in Children after Hematopoietic Stem Cell Transplantation Blood, 2008, 112, 2195-2195.	0.6	0
57	Incidence of Veno-Occlusive Disease with IV in Busulfan Children Is Higher Than Expected: Preliminary Results of the VOD-DF Trial Blood, 2009, 114, 3344-3344.	0.6	O
58	Allogeneic Hematopoetic Stem Cell Transplantation (SCT) In Children with ALL: Outcome of Matched Sibling Donor SCT (MSD-SCT) Is Equivalent to Unrelated Well Matched Donor HSCT (MD-HSCT) A Report From the Prospective International Multicenter Trial ALL-SCT-BFM 2003. Blood, 2010, 116, 530-530.	0.6	0
59	Incidence and Risk Factors for Secondary Autoimmune Diseases (AD) After Hematopoietic Stem Cell Transplantation (HSCT) for a Severe Autoimmune Disease-A Retrospective EBMT WP AD Study. Blood, 2010, 116, 2322-2322.	0.6	0